3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended March 31, 2022:
+Added: The following table summarizes the activity, by month, during the three months ended June 30, 2022:
Period Total Number of
4 unchanged sentences
Dollar Value) of
−Removed: Shares (or Units)
−Removed: that May Yet Be
+Added: Shares that May Yet Be
Purchased Under
−Removed: January 46,642 $ 3.96 $ 4,595,056
−Removed: February 37,910 3.42 4,465,495
−Removed: March 89,597 (1)
+Added: April 28,036 $ 2.68 $ 4,138,402
+Added: May 31,608 2.31 4,065,543
+Added: June 23,673 (1)
2.05 4,016,898
−Removed: Total 174,149
(1) Of this amount, 424 shares were repurchased directly through private purchases at the then-current fair market value of common stock.
−Removed: 10.1* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between A.J.
−Removed: Kazimi and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.11 of the Company’s Annual Report on Form 10-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
−Removed: 10.2* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between Leo B.
−Removed: Pavliv and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.13 of the Company’s Annual Report on Form 10-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
−Removed: 10.3* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between John M.
−Removed: Hamm and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.14 of the Company’s Annual Report on Form 10-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
−Removed: 10.4* Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between James L.
−Removed: Herman and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.15 of the Company’s Annual Report on Form 10-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 11, 2022).
−Removed: 10.5* Seventh Amendment to Revolving Credit Loan Agreement , dated as of March 31 , 202 2 , by and between Cumberland Pharmaceuticals Inc.
+Added: 10.1* Eighth Amendment to Revolving Credit Loan Agreement, dated as of June 30, 2022, by and between Cumberland Pharmaceuticals Inc.
and Pinnacle Bank.
14 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: May 13, 2022 By:
+Added: August 12, 2022 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.